---
title: "Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma share sale worth $137"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293246453.md"
description: "Innovative Cellular Therapeutics Holdings disclosed the sale of 10 Lyell Immunopharma common shares on July 17, 2026. The transaction occurred at a price of USD 13.7 per share. Following this sale, the seller, identified as a 10% owner, retains a holding of 2,857,480 shares."
datetime: "2026-07-20T18:56:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293246453.md)
  - [en](https://longbridge.com/en/news/293246453.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293246453.md)
generator: "portal-rs"
---

# Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma share sale worth $137

-   Innovative Cellular Therapeutics Holdings Ltd disclosed a sale of 10 Lyell Immunopharma common shares on July 17, 2026. \* Shares were sold at USD 13.7, leaving the holder with 2,857,480 shares. \* The filing lists the seller as a 10% owner. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-028955), on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)

## Related News & Research

- [Lyell net loss widens to $44.76 million in Q2 FY26; revenue drops to $4,000](https://longbridge.com/en/news/295142190.md)
- [Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner](https://longbridge.com/en/news/290241000.md)
- [Wearable Devices director Avichay Vardi files initial beneficial ownership statement](https://longbridge.com/en/news/296792445.md)
- [Ebara publishes Investor’s Guide 2026 factsheet](https://longbridge.com/en/news/296725222.md)
- [10:41 ETDeepCura Unveils the Electronic Health Workforce (EHW) -- the Step Beyond the EHR](https://longbridge.com/en/news/296803806.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**